tetano
Editor, Senior Moderator
AIDS. 2012 Sep 26. [Epub ahead of print]
Long term immunogenicity of two doses of 2009 A/H1N1 v vaccine with and without AS03A-adjuvant in HIV-1-infected adults: ANRS 151 Randomized HIFLUVAC Trial.
Durier C, Desaint C, Lucht F, Girard PM, L?vy Y, May T, Michelet C, Rami A, Roman F, Delfraissy JF, Aboulker JP, Launay O; for the ANRS 151 study group and the REIVAC network.
Source
aInserm, SC10, Villejuif, France bUniversit? Paris Descartes; Assistance-Publique H?pitaux de Paris (AP-HP), H?pital Cochin, CIC de Vaccinologie Cochin-Pasteur; Inserm, CIC BT505, Paris, France cInserm, CIC CIE3, H?pital Bellevue, Saint-Etienne, France dAP-HP, H?pital Saint-Antoine, Paris, France eAP-HP, Groupe Henri-Mondor Albert-Ch?nevier, Immunologie clinique; INSERM, Unit? U955; Universit? Paris-Est, Facult? de M?decine, UMR-S955 Cr?teil, France fH?pital de Brabois, Vandoeuvre-l?s-Nancy, France gH?pital Pontchaillou, Rennes, France hAP-HP, H?pital Lariboisi?re, Paris, France iGlaxoSmithKline Biologicals, Rixensart, Belgium jH?pital de Bic?tre, Le Kremlin-Bic?tre, France. *Study group members are listed after the text.
Abstract
OBJECTIVE:
In immunocompromised patients, alternative schedules more immunogenic than the standard influenza vaccine regimen are necessary to enhance and prolong vaccine efficacy. We previously reported that the AS03A-adjuvanted 2009 A/H1N1 v vaccine yielded a higher short term immune response than the unadjuvanted one in HIV-1-infected adults. This study reports the long term persistence of the immune response.
DESIGN AND METHODS:
In a prospective, multicenter, randomized, patient-blinded trial, two doses of AS03A-adjuvanted H1N1 v vaccine containing 3.75 μg hemagglutinin (n = 155; group A) or non-adjuvanted H1N1 v vaccine containing 15 μg hemagglutinin (n = 151; group B), were administered 21 days apart.Hemagglutination inhibition (HI) and neutralizing antibodies were assessed 6 and 12 months after vaccination.
RESULTS:
In group A and B, the seroprotection rates were 83.7% and 59.4% at month 6, 70.4% and 49.3% at month 12, respectively. In a multivariate analysis, persistence of seroprotection 12 months after vaccination was negatively associated with current smoking (odds ratio [OR] = 0.6, p = 0.03) and positively related with the AS03A-adjuvanted H1N1 v vaccine (OR = 2.7, p = 0.0002).
CONCLUSION:
In HIV-1-infected adults, two doses of adjuvanted influenza vaccine induce long term persistence of immune response up to one year after vaccination.
PMID:
23018437
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23018437
Long term immunogenicity of two doses of 2009 A/H1N1 v vaccine with and without AS03A-adjuvant in HIV-1-infected adults: ANRS 151 Randomized HIFLUVAC Trial.
Durier C, Desaint C, Lucht F, Girard PM, L?vy Y, May T, Michelet C, Rami A, Roman F, Delfraissy JF, Aboulker JP, Launay O; for the ANRS 151 study group and the REIVAC network.
Source
aInserm, SC10, Villejuif, France bUniversit? Paris Descartes; Assistance-Publique H?pitaux de Paris (AP-HP), H?pital Cochin, CIC de Vaccinologie Cochin-Pasteur; Inserm, CIC BT505, Paris, France cInserm, CIC CIE3, H?pital Bellevue, Saint-Etienne, France dAP-HP, H?pital Saint-Antoine, Paris, France eAP-HP, Groupe Henri-Mondor Albert-Ch?nevier, Immunologie clinique; INSERM, Unit? U955; Universit? Paris-Est, Facult? de M?decine, UMR-S955 Cr?teil, France fH?pital de Brabois, Vandoeuvre-l?s-Nancy, France gH?pital Pontchaillou, Rennes, France hAP-HP, H?pital Lariboisi?re, Paris, France iGlaxoSmithKline Biologicals, Rixensart, Belgium jH?pital de Bic?tre, Le Kremlin-Bic?tre, France. *Study group members are listed after the text.
Abstract
OBJECTIVE:
In immunocompromised patients, alternative schedules more immunogenic than the standard influenza vaccine regimen are necessary to enhance and prolong vaccine efficacy. We previously reported that the AS03A-adjuvanted 2009 A/H1N1 v vaccine yielded a higher short term immune response than the unadjuvanted one in HIV-1-infected adults. This study reports the long term persistence of the immune response.
DESIGN AND METHODS:
In a prospective, multicenter, randomized, patient-blinded trial, two doses of AS03A-adjuvanted H1N1 v vaccine containing 3.75 μg hemagglutinin (n = 155; group A) or non-adjuvanted H1N1 v vaccine containing 15 μg hemagglutinin (n = 151; group B), were administered 21 days apart.Hemagglutination inhibition (HI) and neutralizing antibodies were assessed 6 and 12 months after vaccination.
RESULTS:
In group A and B, the seroprotection rates were 83.7% and 59.4% at month 6, 70.4% and 49.3% at month 12, respectively. In a multivariate analysis, persistence of seroprotection 12 months after vaccination was negatively associated with current smoking (odds ratio [OR] = 0.6, p = 0.03) and positively related with the AS03A-adjuvanted H1N1 v vaccine (OR = 2.7, p = 0.0002).
CONCLUSION:
In HIV-1-infected adults, two doses of adjuvanted influenza vaccine induce long term persistence of immune response up to one year after vaccination.
PMID:
23018437
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23018437